Degenerative Osteoarthritis Clinical Trial
Official title:
Continuous Distal Adductor Canal Block With Periarticular Local Anesthetic Infiltration Versus Continuous Distal Adductor Canal Block Alone for Analgesia After Total Knee Arthroplasty
NCT number | NCT05427019 |
Other study ID # | 4-2022-0508 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 17, 2022 |
Est. completion date | May 2024 |
Verified date | January 2024 |
Source | Yonsei University |
Contact | Yong Seon Choi |
Phone | 82-2-2224-3919 |
yschoi[@]yuhs.ac | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Continuous administration of local anesthetics to the distal adductor canal could spread into the popliteal fossa and contribute to analgesic effects on posterior knee pain. Periarticular local anesthetic infiltration is a component of multimodal joint pathways and the posterior knee capsule was among the tissues routinely infiltrated. It is expected that there will be overlapping effects of distal adductor canal block and periarticular injection. Therefore, we aim to compare the postoperative pain in the group that received only continuous distal adductor canal block and the group that received both continuous distal adductor canal block and periarticular injection. Sixty-six patients scheduled for total knee arthroplasty will be randomly divided into the two groups. In group 1, the adductor canal catheter is inserted 2cm above the adductor hiatus. In group 2, the adductor canal catheter is inserted where the nerve block performed in group 1 and periarticular injection are performed intraoperatively.
Status | Recruiting |
Enrollment | 66 |
Est. completion date | May 2024 |
Est. primary completion date | May 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Patients aged 19 years old or older, with American Society of Anesthesiologists Physical Status 1-3, and scheduled for elective unilateral total knee arthroplasty Exclusion Criteria: 1. Allergy or intolerance to any of the drugs used in the study 2. Hepatic or renal insufficiency 3. Opioid dependency 4. Coagulopathy 5. Pre-existing neurologic or anatomic deficits in the lower extremities 6. Severe psychiatric illness |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Yonsei University Health System, Severance Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Yonsei University |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Numeric rating scale pain score | Pain intensity at rest evaluated by an 11-point numeric rating scale (NRS: 0 = no pain, 10 = worst imaginable pain) | postoperative 1 day morning (08:00-09:00 AM) | |
Secondary | Numeric rating scale pain score | Pain intensity at rest evaluated by an 11-point numeric rating scale (NRS: 0 = no pain, 10 = worst imaginable pain) | postoperative 6 hours, postoperative 1 day afternoon (4:00-5:00 PM), postoperative 2 day morning (08:00-09:00 AM) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Active, not recruiting |
NCT03203330 -
A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee
|
Phase 3 | |
Not yet recruiting |
NCT05276011 -
A Study to Determine the Safety and Efficacy of TG-C in Subjects With Symptomatic Early Hip Osteoarthritis
|
Phase 2 | |
Active, not recruiting |
NCT03685110 -
CoreHip - Post Market Clinical Follow-Up Study
|
||
Recruiting |
NCT05742763 -
Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis
|
Phase 1/Phase 2 | |
Completed |
NCT02802085 -
VEGA Prospective Kiel
|
||
Completed |
NCT01335243 -
Efficacy and Safety Study of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Bone Marrow
|
Phase 2 | |
Completed |
NCT02756702 -
All Polyethylene Tibia-VEGA Kiel
|
||
Not yet recruiting |
NCT02776943 -
UCMSC Transplantation in the Treatment of Cartilage Damage
|
Phase 1/Phase 2 | |
Completed |
NCT01626677 -
Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect
|
Phase 3 | |
Completed |
NCT01413061 -
Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft
|
N/A | |
Completed |
NCT06254976 -
Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 Levels in Knee Osteoarthritis
|
N/A | |
Completed |
NCT03817632 -
Orthopilot Elite Post-Market Clinical Follow-Up
|
||
Recruiting |
NCT02687399 -
Determine the Efficacy of TT-173. Reducing the the Total Blood Loss Associated With Total Knee Arthroplasty (HESTAT)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03849885 -
Cutibacterium Dermal Colonization: Implications for Total Hip Arthroplasty
|
Phase 4 | |
Completed |
NCT03442855 -
Non-Interventional, Multicenter Bicontact® E PMCF Study
|
||
Active, not recruiting |
NCT03291470 -
Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee
|
Phase 3 | |
Completed |
NCT05291130 -
AESCULAP® Plasmafit® Cementless Acetabular System With Vitelene® Vitamin E Stabilized Highly Crosslinked Polyethylene
|
||
Active, not recruiting |
NCT04255966 -
Plasmafit® Revision Structan® Hip Endoprosthesis Cup
|